NCT06492759 2026-04-17
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Emory University
Phase 2 Recruiting
Clinical Trials
11 trialsNCT07336238 2026-04-17
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
University of Washington
Phase 2 Recruiting
NCT07524894 2026-04-15
SNIFF
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 2 Not yet recruiting
NCT07530224 2026-04-15
JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis
Hangzhou Cancer Hospital
Phase 2 Not yet recruiting
NCT07526597 2026-04-13
STOP-CLL-DCT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT03519412 2026-03-03
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Completed
NCT03568188 2026-02-24
FOCALE
Hospices Civils de Lyon
Phase 2 Completed
NCT07293910 2026-02-13
Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection
Tanta University
Phase 2 Recruiting
NCT07406724 2026-02-12
HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
NCT07077512 2026-01-21
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Sun Yat-sen University
Phase 2 Recruiting
NCT07339553 2026-01-21
Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.
Peking University Third Hospital
Phase 2 Not yet recruiting